Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olitigaltin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 known ✓ | P17931 | 20/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 13/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olitigaltin SCHEMBL18556517 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17935223 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL19678765 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17124625 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17129860 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL23939583 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17460749 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17460870 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17252722 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17432857 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688713-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2017-06-27 | — | — | US | disclosed |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | GALECTO BIOTECH AB (DK) | 2017-04-06 | — | — | US | disclosed |
| US-9580456-B2 | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis | GALECTO BIOTECH AB (DK) | 2017-02-28 | — | — | US | disclosed |
| US-20160096861-A1 | Novel galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2016-04-07 | — | — | US | disclosed |
| US-9243021-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2016-01-26 | — | — | US | disclosed |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150274764-A1 | Galactoside Inhibitor of Galectin-3 and its use for Treating Pulmonary Fibrosis | GALECTO BIOTECH AB (DK) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | LGALS1, LGALS2, LGALS3BP | LGALS3 4/4885LGALS1 1/4885LGALS8 5/4885 |
| US-20150274764-A1 | Galactoside Inhibitor of Galectin-3 and its use for Treating Pulmonary Fibrosis | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS1 2/4885LGALS8 7/4885 |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 5/4885 |
| US-20160096861-A1 | Novel galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.